Extending Survival for Patients With TNBC: Are You Up to Date on New Treatment Standards?
This accredited CME/CE publication reviews current data from late-stage clinical trials on checkpoint-inhibitor use in advanced and metastatic triple negative breast cancer (TNBC). It also identifies immune-related adverse events associated with these treatments, provides strategies to manage such events, and offers patient-monitoring recommendations. These discussions are framed in the context of providing care for those with TNBC within the Veterans Health Administration. Read More